VXRT News and Press, Vaxart Inc. From 11/13/25

2025-11-13 10:00:00 ET Read the full article on Seeking Alpha For further details see: Here are the major earnings after the close Thursday

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

2025-11-12 11:06:21 ET More on Vaxart Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart Financial information for Vaxart ...

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced...

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program PR Newswire HEPLISAV-B® quarterly net product revenue of $90 million , a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance r...

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program PR Newswire Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine op...

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research...

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announce...

2025-09-19 09:19:31 ET More on Vaxart Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 27th Annual Global Investment Conference - Slideshow Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript Vaxart outlines accelerated COVID-19 trial data timeline and plans noroviru...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced tha...